Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study

David Pereyra; Stefan Heber; Waltraud Schrottmaier; Jonas Santol; Anita Pirabe; Anna Schmuckenschlager; Kerstin Kammerer; Daphni Ammon; Thomas Sorz; Fabian Fritsch; Hubert Hayden; Erich Pawelka; Philipp Krüger; Benedikt Rumpf; Marianna Traugott; Pia Glaser; Christa Firbas; Christian Schörgenhofer; Tamara Seitz; Mario Karolyi; Ingrid Pabinger; Christine Brostjan; Patrick Starlinger; Guenter Weiss; Rosa Bellmann-Weiler; Helmut Salzer; Bernd Jilma; Alexander Zoufaly; Alice Assinger

doi:10.1093/cvr/cvab308

Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study

David Pereyra
, Stefan Heber
, Waltraud Schrottmaier
, Jonas Santol
, Anita Pirabe
, Anna Schmuckenschlager
, Kerstin Kammerer
, Daphni Ammon
, Thomas Sorz
, Fabian Fritsch
, Hubert Hayden
, Erich Pawelka
, Philipp Krüger
, Benedikt Rumpf
, Marianna Traugott
, Pia Glaser
, Christa Firbas
, Christian Schörgenhofer
, Tamara Seitz
, Mario Karolyi

Ingrid Pabinger, Christine Brostjan, Patrick Starlinger, Guenter Weiss, Rosa Bellmann-Weiler, Helmut Salzer, Bernd Jilma, Alexander Zoufaly, Alice Assinger

Department of Internal Medicine 4 - Pneumology and Infectious Diseases

Research output: Contribution to journal › Article › peer-review

Abstract

Anticoagulation was associated with improved survival of hospitalized coronavirus disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-associated coagulopathy (CAC) and the mechanism responsible for improved survival of anticoagulated patients with COVID-19 remain largely elusive. This investigation aimed to explore the effects of anticoagulation and low-molecular-weight heparin (LMWH) in particular on patient outcome, CAC development, thromboinflammation, cell death, and viral persistence.

Original language	English
Pages (from-to)	2807-2820
Number of pages	14
Journal	Cardiovascular Research
Volume	117
Issue number	14
DOIs	https://doi.org/10.1093/cvr/cvab308
Publication status	Published - Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Fields of science

303 Health Sciences
304 Medical Biotechnology
305 Other Human Medicine, Health Sciences
301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine

Access to Document

10.1093/cvr/cvab308

Cite this

Pereyra, D., Heber, S., Schrottmaier, W., Santol, J., Pirabe, A., Schmuckenschlager, A., Kammerer, K., Ammon, D., Sorz, T., Fritsch, F., Hayden, H., Pawelka, E., Krüger, P., Rumpf, B., Traugott, M., Glaser, P., Firbas, C., Schörgenhofer, C., Seitz, T., ... Assinger, A. (2021). Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study. Cardiovascular Research, 117(14), 2807-2820. https://doi.org/10.1093/cvr/cvab308

@article{75c0824df74a43e6ad9504611b0caf7f,

title = "Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study",

abstract = "Anticoagulation was associated with improved survival of hospitalized coronavirus disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-associated coagulopathy (CAC) and the mechanism responsible for improved survival of anticoagulated patients with COVID-19 remain largely elusive. This investigation aimed to explore the effects of anticoagulation and low-molecular-weight heparin (LMWH) in particular on patient outcome, CAC development, thromboinflammation, cell death, and viral persistence.",

author = "David Pereyra and Stefan Heber and Waltraud Schrottmaier and Jonas Santol and Anita Pirabe and Anna Schmuckenschlager and Kerstin Kammerer and Daphni Ammon and Thomas Sorz and Fabian Fritsch and Hubert Hayden and Erich Pawelka and Philipp Kr{\"u}ger and Benedikt Rumpf and Marianna Traugott and Pia Glaser and Christa Firbas and Christian Sch{\"o}rgenhofer and Tamara Seitz and Mario Karolyi and Ingrid Pabinger and Christine Brostjan and Patrick Starlinger and Guenter Weiss and Rosa Bellmann-Weiler and Helmut Salzer and Bernd Jilma and Alexander Zoufaly and Alice Assinger",

year = "2021",

month = dec,

doi = "10.1093/cvr/cvab308",

language = "English",

volume = "117",

pages = "2807--2820",

journal = "Cardiovascular Research",

issn = "0008-6363",

publisher = "Oxford University Press",

number = "14",

}

Pereyra, D, Heber, S, Schrottmaier, W, Santol, J, Pirabe, A, Schmuckenschlager, A, Kammerer, K, Ammon, D, Sorz, T, Fritsch, F, Hayden, H, Pawelka, E, Krüger, P, Rumpf, B, Traugott, M, Glaser, P, Firbas, C, Schörgenhofer, C, Seitz, T, Karolyi, M, Pabinger, I, Brostjan, C, Starlinger, P, Weiss, G, Bellmann-Weiler, R, Salzer, H, Jilma, B, Zoufaly, A & Assinger, A 2021, 'Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study', Cardiovascular Research, vol. 117, no. 14, pp. 2807-2820. https://doi.org/10.1093/cvr/cvab308

TY - JOUR

T1 - Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study

AU - Pereyra, David

AU - Heber, Stefan

AU - Schrottmaier, Waltraud

AU - Santol, Jonas

AU - Pirabe, Anita

AU - Schmuckenschlager, Anna

AU - Kammerer, Kerstin

AU - Ammon, Daphni

AU - Sorz, Thomas

AU - Fritsch, Fabian

AU - Hayden, Hubert

AU - Pawelka, Erich

AU - Krüger, Philipp

AU - Rumpf, Benedikt

AU - Traugott, Marianna

AU - Glaser, Pia

AU - Firbas, Christa

AU - Schörgenhofer, Christian

AU - Seitz, Tamara

AU - Karolyi, Mario

AU - Pabinger, Ingrid

AU - Brostjan, Christine

AU - Starlinger, Patrick

AU - Weiss, Guenter

AU - Bellmann-Weiler, Rosa

AU - Salzer, Helmut

AU - Jilma, Bernd

AU - Zoufaly, Alexander

AU - Assinger, Alice

PY - 2021/12

Y1 - 2021/12

N2 - Anticoagulation was associated with improved survival of hospitalized coronavirus disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-associated coagulopathy (CAC) and the mechanism responsible for improved survival of anticoagulated patients with COVID-19 remain largely elusive. This investigation aimed to explore the effects of anticoagulation and low-molecular-weight heparin (LMWH) in particular on patient outcome, CAC development, thromboinflammation, cell death, and viral persistence.

AB - Anticoagulation was associated with improved survival of hospitalized coronavirus disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-associated coagulopathy (CAC) and the mechanism responsible for improved survival of anticoagulated patients with COVID-19 remain largely elusive. This investigation aimed to explore the effects of anticoagulation and low-molecular-weight heparin (LMWH) in particular on patient outcome, CAC development, thromboinflammation, cell death, and viral persistence.

UR - https://www.scopus.com/pages/publications/85121735705

U2 - 10.1093/cvr/cvab308

DO - 10.1093/cvr/cvab308

M3 - Article

SN - 0008-6363

VL - 117

SP - 2807

EP - 2820

JO - Cardiovascular Research

JF - Cardiovascular Research

IS - 14

ER -

Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study

Abstract

UN SDGs

Fields of science

Access to Document

Other files and links

Cite this